Financial reports

Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway.

Headquarter is in Malmö, Sweden, and the company’s shares are listed on Nasdaq Stockholm (ticker: ACE)

Ascelia Pharma company presentation Oct 2021 (pdf)

Q2 2021 presentation (pdf), link to webcast

…
PREVIOUS CAPITAL MARKET DAYS

• 2021-10-19Ascelia Pharma’s Food Effect Study with Orviglance successfully completed
• 2021-09-21Ascelia Pharma Signs Clinical Collaboration Agreement With Taiho Oncology, Inc. for the Development of Oncoral in Combination with LONSURF®
• 2021-08-19Quarterly Report Q2 2021: Preparing Oncoral for the next level
• 2021-08-18Covid-19 extends recruitment period of SPARKLE study
• 2021-08-13Abstract for Orviglance comparison study to gadolinium accepted at the world’s largest radiology conference RSNA

• October 28 @ 19:00 - 19:20

  Redeye Investor Forum Malmö

• November 4 @ 08:00

  Interim report 9M (January-September 2021)

• November 11

  Redeye Life Science Day

• November 30 - December 2

  Danske Bank’s Winter Seminar

• 2022-02-10 @ 08:00

  Full year report 2021 (January-December 2021)